After having caught up with Insulet (PODD) management regarding the new 2026 Home Health Prospective Payment System proposal, BofA analyst Travis Steed reports that the company is confirming, “as we expected,” that it does not fall under competitive bidding program given that it falls under the Part D pharmacy portion of Medicare and the proposal released last week impacts the Part B portion of Medicare. BofA maintains its Buy rating and $335 price target on Insulet, citing its market position in type 2 diabetes and patch pump and margin expansion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Wells says CBP proposal for CGMs expected, insulin pumps inclusion ‘a surprise’
- Diabetes device maker shares slide after payment scheduling proposal
- Diabetes stocks rally after RFK comments on HHS campaign
- Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
- Insulet initiated with a Buy at Truist